Physician profile
Stephan C Kurylas
NPI 1407883903
$34,904.71
in general payments reported to CMS, 2019-2025
65 companies · $4,975 in 2025
The $4,975 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,138 · 2020: $3,241 · 2021: $6,462 · 2022: $5,572 · 2023: $5,459 · 2024: $4,057 · 2025: $4,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,490.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,761.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $2,810.94 | 2019-2023 | |
| Abbvie INC. | $2,365.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,298.62 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $2,014.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,747.71 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Biohaven Pharmaceuticals, INC. | $1,713.34 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,697.38 | 2019-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $1,215.30 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Lilly USA, LLC | $1,169.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $1,093.02 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Supernus Pharmaceuticals, INC. | $945.79 | 2019-2025 | Qelbree, Xyosted, Tlando |
| Neos Therapeutics, LP | $882.30 | 2019-2023 | Adzenys Xr-Odt |
| Antares Pharma, INC. | $872.63 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $848.19 | 2021-2024 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $725.63 | 2021-2025 | Rexulti |
| Horizon Therapeutics Plc | $722.95 | 2019-2023 | Krystexxa |
| Esperion Therapeutics, INC. | $705.90 | 2020-2025 | Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $634.09 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $543.21 | 2019-2025 | |
| Abbott Laboratories | $490.10 | 2019-2025 | Freestyle Libre 3 |
| Corium, LLC | $483.18 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $458.99 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.71 | 2019-2025 | Jardiance |
| Tris Pharma INC | $385.79 | 2022-2025 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $372.70 | 2021-2023 | Gvoke Hypopen, Recorlev |
| Allergan, INC. | $370.88 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $346.52 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $215.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $195.94 | 2022 | |
| Clarus Therapeutics INC. | $191.53 | 2021 | |
| Sumitomo Pharma America, INC. | $174.79 | 2024-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $166.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $164.95 | 2020-2021 | |
| Amarin Pharma, INC. | $164.57 | 2019-2022 | |
| Halozyme INC | $153.87 | 2023 | |
| Genentech USA, INC. | $136.06 | 2019 | |
| Lundbeck LLC | $128.31 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.24 | 2025 | Caplyta |
| Astellas Pharma US INC | $96.81 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $89.82 | 2022-2024 | |
| Eisai INC. | $85.79 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $82.82 | 2019-2022 | |
| Aytu Biopharma, INC. | $67.05 | 2021 | |
| Arbor Pharmaceuticals, INC. | $53.59 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $49.22 | 2024-2025 | Hetlioz, Fanapt |
| Ironwood Pharmaceuticals, INC | $48.96 | 2021-2022 | |
| Medicure Pharma INC. | $39.93 | 2021-2023 | Zypitamag |
| Corcept Therapeutics | $38.41 | 2023-2024 | Korlym |
| Jazz Pharmaceuticals INC. | $35.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $35.82 | 2023 | Quviviq |
| Globus Medical, INC. | $34.85 | 2025 | Senza |
| Acerus Pharmaceuticals Corporation | $24.84 | 2021 | |
| Bausch Health US, LLC | $24.70 | 2025 | Aplenzin |
| Dexcom, INC. | $22.93 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $22.78 | 2019 | |
| Covis Pharma Gmbh | $22.34 | 2019 | |
| Alfasigma USA, INC. | $19.80 | 2022 | |
| Medtronic, INC. | $19.24 | 2024 | Closurefast |
| Nevro Corp. | $16.85 | 2023 | Senza |
| Dermira, INC. | $16.13 | 2020 | |
| Endo Pharmaceuticals INC. | $15.94 | 2022 | |
| Currax Pharmaceuticals LLC | $15.07 | 2024 | Contrave |
| Mylan Specialty L.P. | $13.53 | 2022 | |
| Medtronic Vascular, INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Kurylas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.